Dr. Reddy's Laboratories Limited filings document its U.S. reporting as a foreign private issuer with American depositary receipts listed on the New York Stock Exchange. Recent Form 6-K reports furnish exchange intimations and exhibits submitted to Indian exchanges and the NYSE, including board-meeting notices and other current-report disclosures.
The filing record centers on Rule 13a-16 and 15d-16 submissions, Form 20-F reporting status, governance communications, and public-company notices tied to Dr. Reddy's pharmaceutical operations and securities across India and the United States.
On June 20, 2025, Dr. Reddy’s Laboratories Limited (NYSE: RDY) furnished a routine Form 6-K to the U.S. Securities and Exchange Commission. The filing affirms that the company continues to submit its annual reports on Form 20-F and is not relying on the Rule 12g3-2(b) exemption. The sole attachment is Exhibit 99.1 – “Intimation dated June 20, 2025.” The document was signed by Company Secretary K Randhir Singh. No financial statements, earnings figures, or descriptions of material transactions accompany this report, indicating that the submission is administrative in nature and unlikely to affect the company’s financial outlook or valuation.